Latest Breaking News On - Daniel tass - Page 8 : comparemela.com

DBV Technologies S A : DBV Technologies Provides Clinical Update on VITESSE Phase 3 Trial

DBV Technologies S A : DBV Technologies Provides Clinical Update on VITESSE Phase 3 Trial
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

France generalUnited statesAnne pollakAngela marcucciExchange commissionCompany adssDrug administrationProvides clinical updateStock marketDaniel tassChief executive officerViaskin peanutNorth americanBasking ridgeEuronext parisNasdaq global select market

DBV Technologies Provides Clinical Update on VITESSE Phase 3 Trial

DBV Technologies Provides Clinical Update on VITESSE Phase 3 Trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

France generalUnited statesExchange commissionCompany adssDrug administrationWall streetProvides clinical updateNasdaq stock marketEvaluate safetyDaniel tassChief executive officerNorth americanBasking ridgeEuronext parisNasdaq global select marketLooking statementsthis

DBV Technologies Announces Initiation of Phase 3 Study (VITESSE) Using the Modified Viaskin Peanut Patch in Peanut -Allergic Children Ages 4 to 7 Years

DBV Technologies Announces Initiation of Phase 3 Study (VITESSE) Using the Modified Viaskin Peanut Patch in Peanut -Allergic Children Ages 4 to 7 Years
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesFrance generalUnited kingdomPharis mohideenDavid fleischerExchange commissionCompany adssEthics committeeDrug administrationWall streetModified viaskin peanut patchAllergic children agesInstitutional review boardNasdaq stock marketEvaluate safetyPeanut patch

DBV Technologies S A : DBV Technologies Announces Initiation of Phase 3 Study (VITESSE) Using the Modified Viaskin Peanut Patch in Peanut -Allergic Children Ages 4 to 7 Years

Montrouge, France, September 7, 2022 DBV Technologies Announces Initiation of Phase 3 Study (VITESSE) Using the Modified Viaskin Peanut Patch in Peanut -Allergic Children Ages 4 to 7

United statesFrance generalUnited kingdomAnne pollakAngela marcucciPharis mohideenDavid fleischerExchange commissionCompany adssEthics committeeDrug administrationModified viaskin peanut patchAllergic children agesInstitutional review boardStock marketViaskin peanut patch

DBV Technologies S A : DBV Technologies to Present at Upcoming Investor Conferences

Montrouge, France, September 2, 2022 DBV Technologies to Present at Upcoming Investor Conferences DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage

New yorkUnited statesFrance generalAngela marcucciAnne pollakCompany adssUpcoming investorStock marketDaniel tassChief executive officerIn person conferenceAnnual global investmentHybrid in personVirtual conferenceNorth americanBasking ridge